1Choi KB, Wong F, Harlan JM, et al. Lipopolysaccharide mediates endothelial apoptosis by a FADD-dependent pathway. J Biol Chem,1998, 273: 20185-20188.
2Feld J, Lee JY, Locarnini S. New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. Hepatology,2003, 38: 545-553.
3Perelson AS, Ribeiro RM. Hepatitis B virus linetics and mathematical modeling. Semin Liver Dis, 2004, 24(Suppl 1): 11-16.
4Thimme R, Wieland S, Steiger C, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol, 2003, 77: 68-76.
5Perrillo RP. Overview of treatment of hepatitis B: key approaches and clinical challenges. Semin Liver Dis, 2004, 24(Suppl 1): 23-29.
6Wright TL. Clinical trial results and treatment resistance with Lamivudine for hepatitis B. Semin Liver Dis, 2004, 24(Suppl 1): 31-36.
7Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis, 2004, 24(Suppl 1): 3-10.
8Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology,2003, 125: 1714-1722.
9Liaw YF, Chien RN, Yeh CT. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther, 2004,
10: 257-262.9.Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med, 2003, 348: 808-816.
4Gillen S, Schuster T, Meyer zum B schenfelde C, et al. Preoperative neoadjuvant therapy in pancreatic cancer:a systematic review and meta- analysis of response and resection percentages [ J ]. PLoS Med, 2010,7 (4) : e1000267.
5Berry PA, Antoniades CE, Hussain M J, et al. Admission levels and early chances in serum interleukin-10 are predictive of poor outcome in acute liver failure and decompensated cirrhosis[J]. Livex Int,2010,30(51 ) : 733 - 740.
